| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 4006089 | American Journal of Ophthalmology | 2007 | 9 Pages |
Abstract
IFN-α seems to have significant potential in treatment of severe, sight-threatening refractory uveitis from a variety of causes. A range of adverse events, including IFN-α-associated retinopathy, may occur and could limit the use of this immunomodulatory drug.
Related Topics
Health Sciences
Medicine and Dentistry
Ophthalmology
Authors
Jarka Plskova, Kathrin Greiner, John V. Forrester,